CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Hyojin Kim, Hyun Jung Kwon, Eun Sun Kim, Soohyeon Kwon, Kyoung Jin Suh, Se Hyun Kim, Yu Jung Kim, Jong Seok Lee, Jin-Haeng Chung

Cancer Research and Treatment. 2022;54(2):424-433. Published online 2021 July 7 DOI: https://doi.org/10.4143/crt.2021.583

Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Hyojin Kim, Hyun Jung Kwon, Eun Sun Kim, Soohyeon Kwon, Kyoung Jin Suh, Se Hyun Kim, Yu Jung Kim, Jong Seok Lee, Jin-Haeng Chung

Cancer Research and Treatment. 2022;54(2):424-433

Link1

Link2 Link3

Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors

Fumihiro Shoji, Hiroaki Takeoka, Yuka Kozuma, Gouji Toyokawa, Koji Yamazaki, Masao Ichiki, Sadanori Takeo

Lung Cancer. 2019;136:45-51

Link1 Link2

Sixth-week immune-nutritional-inflammatory biomarkers: Can they predict clinical outcomes in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors?

Polat Olgun, Ömer Diker

. 2023;

Link1 Link2

Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Kei Sonehara, Kazunari Tateishi, Taisuke Araki, Masamichi Komatsu, Jumpei Akahane, Hiroshi Yamamoto, Masayuki Hanaoka

Cancer Management and Research. 2022;Volume 14:427-435

Link1 Link2

Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer

Kazuhiko Shien, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba

Lung Cancer. 2016;99:79-87

Link1 Link2

Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Ryota Ushio, Shuji Murakami, Haruhiro Saito

Journal of Clinical Medicine. 2022;11(7):1855

Link1

Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study

Kenji Sawa, Izumi Sato, Masato Takeuchi, Koji Kawakami

Cancer Immunology, Immunotherapy. 2022;

Link1

Link2 Link3

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)

Nicholas Giustini, Lyudmila Bazhenova

Lung Cancer: Targets and Therapy. 2021;Volume 12:21-34

Link1 Link2

Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors

Brett H. Herzog, Saiama N. Waqar, Siddhartha Devarakonda, Jeffrey P. Ward, Feng Gao, Ramaswamy Govindan, Daniel Morgensztern

Lung Cancer. 2022;173:101-106

Link1 Link2

Comments on ‘The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors’

Kazuki Takada, Shinkichi Takamori, Naoko Miura, Yasunori Shikada, Mototsugu Shimokawa

Clinical Lung Cancer. 2022;23(3):e174-e175

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.